The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
Placebo hair regrowth might be influenced by propylene glycol in lotions or participants lying about using other treatments like minoxidil, finasteride, or microneedling. Being part of a study can also improve hair health due to lifestyle changes.
The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.
RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.
The conversation discusses a user's unconventional hair loss treatment involving scalp massage, dermastamping, and pouring hot water to induce a burning sensation, with a warning not to try it without further evidence. Other users suggest more traditional treatments like Minoxidil and finasteride, while expressing skepticism and concern about the hot water method.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
The conversation discusses skepticism about new hair loss treatments, with many users expressing doubt about their effectiveness compared to existing treatments like minoxidil and finasteride. Some users mention natural oils like olive and macadamia oil, but overall, there's a consensus that these are unlikely to be game changers.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.
The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.
Hair loss can significantly impact self-perception and identity, leading individuals to feel disconnected from their interests and hobbies. Many consider treatments like Minoxidil, finasteride, and hair transplants to address these concerns, but struggle with societal expectations and personal acceptance.
The user is experiencing hair shedding despite using finasteride, minoxidil, and microneedling, and is concerned about the non-linear progress. Other users share similar experiences, suggesting shedding is normal and cyclical, with some recommending less frequent microneedling.
The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.
The user switched from finasteride to Dutasteride 0.5 mg since mid-May and is experiencing shedding but noticing baby hairs, questioning if they are new growth. Consistency with Dutasteride and Minoxidil is advised for better results, with improvements expected after the initial shedding phase.
The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The user has tried RU58841, pyrilutamide, oral minoxidil combined with finasteride or dutasteride for hair loss. They are asking for new and exciting treatments.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
The user is experiencing hair regrowth using finasteride, minoxidil, and KX-826. They regret not starting treatment earlier but are now seeing progress.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
A user is starting a topical finasteride treatment for diffuse patterned alopecia, having previously used minoxidil without success. They are cautious about side effects and have chosen topical over oral finasteride, while also using Nizoral and biotin in their routine.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
A user experienced 12 months of hair shedding on finasteride and is unsure about continuing, increasing the dose, or switching to dutasteride. Suggestions include adding minoxidil, adjusting finasteride dosage, and checking for deficiencies.
The conversation humorously discusses diverting DHT from head to body hair and explores the idea of transplanting body hair to the scalp. It also mentions the potential for treatments to prevent DHT from affecting hair follicles.
A user shared their 3.5-4 month progress using Topical Minoxidil, Oral Finasteride, Keto 1%, and Dermastamp, reporting positive results despite some shedding and flaking. Replies praised the progress and inquired about the treatment routine and temple condition.
The user experienced initial improvement in hair loss with oral finasteride and minoxidil but later faced increased shedding and thinning. They switched to dutasteride, hoping for better results, while continuing topical minoxidil.
Elevated PGD2 levels in bald scalp tissue may contribute to hair loss, and treatments like castor oil, finasteride, and minoxidil are discussed as potential solutions. Some users explore alternatives like oral castor oil and cetirizine for those who cannot use finasteride.